Research Article

Serum Uric Acid as an Independent Risk Factor for the Presence and Severity of Early-Onset Coronary Artery Disease: A Case-Control Study

Ting-Ting Tian, Hui Li, Sheng-Jie Chen, Qing Wang, Qing-Wu Tian, Bei-Bei Zhang, Jie Zhu, Guo-Wei He, Li-Min Lun, and Chao Xuan

1Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China
2Department of Molecular Microbiology, Oslo University Hospital, Oslo, Norway
3Department Scientific Research Management, The Affiliated Hospital of Qingdao University, Qingdao, China
4Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5Department of Surgery, Oregon Health and Science University, Portland, Oregon, USA

Correspondence should be addressed to Li-Min Lun; lunlmqd@163.com and Chao Xuan; bio-x.c@hotmail.com

Received 15 April 2018; Revised 22 July 2018; Accepted 20 September 2018; Published 23 October 2018

Academic Editor: Giuseppe Biondi-Zoccai

Copyright © 2018 Ting-Ting Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Serum uric acid (UA) is the final product of purine metabolism in humans. The present study is aimed at identifying the potential association between serum UA and early-onset coronary artery disease (EOCAD). The study population consisted of 1093 EOCAD patients aged ≤50 years, and 1117 age- and sex-matched apparently healthy people served as controls. The concentrations of UA were measured by uricase method. The severity of CAD was evaluated by Gensini score. The mean serum level of UA was 5.843 ± 1.479 mg/dl in EOCAD patients and 5.433 ± 1.529 mg/dl in controls. Serum UA levels were significantly higher in the EOCAD group than those in the control group (P < 0.001) and was an independent risk factor for EOCAD (OR = 1.100, 95% CI: 1.022–1.185). The early-onset myocardial infarction patients with 3-vessel disease had higher serum UA levels than those with 1- or 2-vessel disease. The serum UA levels of EOCAD patients with acute coronary syndrome were significantly higher than those with chronic coronary artery disease. EOCAD patients with hyperuricemia had higher Gensini scores than those without hyperuricemia. In addition, the serum UA levels were affected by drinking (P < 0.01) and were positively correlated with serum creatinine (r = 0.323) and weight (r = 0.327). Our results show that serum UA was an independent risk factor for EOCAD. The serum UA levels were associated with the presence and severity of EOCAD and suggested that UA may be involved in the progression of EOCAD.

1. Introduction

Uric acid (UA) is the end product of purine nucleotide metabolism, formed from the breakdown of adenosine and guanine [1]. UA is a weak acid with a pH of 5.8. UA mainly exists as urate, the salt of UA, and is excreted in urine [2]. The solubility of UA in human blood is low. When the serum level of UA is higher than the solubility limit (6.8 mg/dl), crystals of UA form as monosodium urate [3].

Nitric oxide (NO) plays important roles in the regulation of vascular tone and structure [4]. Decreasing in the production and the bioavailability of NO is an important symbol of endothelial dysfunction [5]. UA is involved in the reduction of NO bioavailability via a variety of mechanisms in endothelial cells, including blocking uptake of L-arginine, stimulating L-arginine degradation, and by scavenging of NO from UA-generated oxidants or by UA itself [6]. It has been reported that UA inhibits the NO-dependent dilation of isolated aortic rings in rats [7]. In addition, it is well known that crystal UA can induce an inflammatory response [8], and soluble uric acid has been demonstrated to induce vascular smooth muscle cell proliferation in vitro [9]. Therefore,
UA may play an endogenous danger role in cardiovascular disease. Many studies have also demonstrated that serum level of UA is associated with cardiovascular diseases [10].

Compared with late-onset coronary heart disease, early-onset coronary heart disease (EOCAD) has particular components of etiology, including family heredity, lipid metabolism, gender composition, and risk factors [11–13]. For instance, our previous study also found that the MTHFR gene C677T polymorphism was associated with risk of early-onset myocardial infarction (MI) but not in late-onset MI in Caucasians [14]. Many previous studies have suggested that serum UA is an important risk factor for coronary artery disease (CAD). However, we have found few studies considering the relationship between the serum levels of UA and risk of EOCAD. This study is being planned to investigate whether there is an association between serum UA levels and the presence and severity of EOCAD.

2. Materials and Methods

2.1. Study Subjects. This study was a hospital-based case-control study conducted in patients attending The Affiliated Hospital of Qingdao University from January 2013 to June 2017. The 1093 EOCAD patients were aged ≤50 years in their first onset of symptoms and hospitalization for coronary angiography. All patients fulfilled the criteria of stable chest pain and/or signs of myocardial ischemia on exercise electrocardiography. EOCAD was assessed by review of patients’ angiograms by their treating cardiologists. Patients having history of chronic infection diseases, abnormal kidney function, pregnancy, and neoplastic disease and patients on treatment with drugs (diuretics, allopurinol) were excluded from the study. Age- and sex-matched apparently healthy people (n = 1117), free from any signs or symptoms of cardiovascular disease, served as control. They were recruited from a geographic background similar to that of the patients and came from community samples or hospital employees. Written informed consent was obtained from each patient included in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was conducted in accordance with the guidelines set by the Ethics Committee of The Affiliated Hospital of Qingdao University.

2.2. Anthropometric and Clinical Parameters. A full physical examination of all the subjects was carried out, and data involving smoking and drinking habits, body mass index (BMI), age at onset of CAD symptoms, MI, hypertension, diabetes mellitus, and dyslipidemia were recorded. Height and weight were recorded to the nearest 0.5 cm and 0.1 kg, respectively. The BMI was calculated by using the formula: body weight in kilograms divided by height in meters squared. Systolic and diastolic blood pressure was measured twice at an interval of 30 min using the automated oscillometric device. An average value of the two readings was considered. Diagnosis of hypertension was based on the presence of elevated systolic (≥140 mmHg) and/or diastolic (≥90 mmHg) blood pressure. Diabetes mellitus (DM) was diagnosed when the subject casual fasting glucose level ≥ 7.8 mmol/l, ≥11.1 mmol/l at 2 h after an oral glucose challenge or both.

2.3. Evaluation of CAD Severity. Coronary angiography was used to identify the number of diseased vessels in MI patients. Four major coronary artery branches (left main, left anterior descending, left circumflex, and right coronary artery) were evaluated, and a luminal stenosis degree of 50% or more was defined as a significant lesion. Patients were defined as having single, double, or triple branch involvement if they had one, two, and three or more branches involved, respectively.

The severity of CAD was calculated for each patient by the Gensini score system. The Gensini score is a point scale based upon the number of stenotic coronary artery segments, including the degree of luminal narrowing (the score was from 1 to 32) and the localization of the stenosis (the score was from 0.5 to 5). Thus, the Gensini score is calculated as a sum of stenosis score and functional significance score calculated for each segment of the coronary artery tree.

2.4. Biochemical Measurements. Blood samples were drawn from all participants after an overnight fasting of at least eight hours. Serum levels of fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and serum creatinine (SCr), Lipoprotein (a) (Lp (a)), and uric acid (UA) were determined by using the automatic biochemistry analyzer (Hitachi HCP-7600, Japan).

2.5. Statistical Analysis. All data were analyzed with SPSS statistical software (version 13.0; SPSS Inc., Chicago, Illinois, USA). Values are means ± standard deviation (SD) if not otherwise specified. The distribution of categorical variables was expressed as frequencies and percentages and the comparisons calculated by using chi-square test or Fisher exact test, as appropriate. Comparisons between groups for study variables were done using the unpaired Student’s t-test or one-way ANOVA for normally distributed parameters. Spearman correlation coefficients were used to discern interrelationships. Logistic regression was used to test the interactive effects of other variables on the observed association between serum UA and EOCAD. All tests were two-sided, and throughout, P < 0.05 was considered statistically significant.

3. Results

3.1. Baseline Characteristics. A total of 1093 EOCAD patients and 1117 controls matched for age and gender were enrolled into the study. The demographic and clinical characteristics of the study population are shown in Table 1.

The EOCAD patients had higher values of BMI, FBG, TG, LDL-C, and Lp (a), whereas they displayed lower concentrations of HDL-C. Specifically, both groups had similar gender composition, age, serum TC levels, and SCr levels. In addition, the patients had higher smoking and drinking rate compared with controls. 633 patients were diagnosed as MI in the EOCAD group, including 326 patients with 1-vessel disease, 199 patients with 2-vessel disease, and 108 patients with 3-vessel disease. The drinking status could...
significantly increase the serum UA levels in the male control group \((5.713 \pm 1.505 \text{ mg/dl vs. } 5.463 \pm 1.483 \text{ mg/dl, } P < 0.01, \text{ Figure 1(a)) but not in the male EOCAD patient group \((5.966 \pm 1.464 \text{ mg/dl vs. } 5.981 \pm 1.393 \text{ mg/dl, } P > 0.05). The smoking status has no effect on the serum UA levels in male control \((5.644 \pm 1.453 \text{ mg/dl vs. } 5.503 \pm 1.522 \text{ mg/dl, } P > 0.05) \text{ and EOCAD groups \((6.002 \pm 1.502 \text{ mg/dl vs. } 5.931 \pm 1.372 \text{ mg/dl, } P > 0.05)\). In addition, we found that serum UA levels were weakly correlated with \text{Scr} \((r = 0.247, P < 0.000 \text{ in the EOCAD group and } r = 0.323, P < 0.001 \text{ in the control group, Figure 1(b))}. Serum UA levels were positively correlated with weight \((r = 0.327, P < 0.001, \text{ Figure 1(c)) in the control group.}

### 3.2. The Relationship between Serum UA Levels and Risk of EOCAD

To examine the relationship between serum UA levels and risk of EOCAD, serum UA levels were measured in all 2210 subjects. The mean serum level of serum UA was \(5.843 \pm 1.479 \text{ mg/dl in EOCAD patients and } 5.433 \pm 1.529 \text{ mg/dl in controls. Serum UA levels were significantly higher in the EOCAD group than those in the control group \(( \text{unpaired } t\text{-test, } P < 0.001, \text{ Figure 2). Serum UA levels were significantly higher in the female EOCAD group \((4.718 \pm 1.343 \text{ mg/dl)} \text{ than those in the female control group \((4.178 \pm 1.311 \text{ mg/dl, unpaired } t\text{-test, } P < 0.01, \text{ Figure 3). The same relationship was also detected in the male EOCAD \((5.965 \pm 1.442 \text{ mg/dl) and male control group \((5.560 \pm 1.492 \text{ mg/dl, unpaired } t\text{-test, } P < 0.001, \text{ Figure 3). }}

By logistic regression analysis, after adjusting for age, gender, BMI, diabetes, hypertension, smoking status, and drinking status, the association between UA and EOCAD was detected \((OR = 1.150, 95\% \text{ CI: } 1.075–1.229; P < 0.001). After adjustment for \text{Glu, LDL-C, Scr, TG, TC, HDL-C, and Lp (a)} \text{, UA remained as a significant factor that correlated with EOCAD \((OR = 1.139, 95\% \text{ CI: } 1.065–1.218; P < 0.001). After further adjustment for all these factors, UA remained as an independent risk factor for EOCAD \((OR = 1.100, 95\% \text{ CI: } 1.022–1.185; P = 0.011) \text{ (Table 2).}

### 3.3. The Relationship between Serum UA Levels and Severity of EOCAD

The serum UA levels in EOCAD patients with stable angina, unstable angina, and MI were \(5.554 \pm 1.419 \text{ mg/dl \((n = 101), 5.886 \pm 1.505 \text{ mg/dl \((n = 344), and } 5.880 \pm 1.479 \text{ mg/dl \((n = 633), \text{ respectively. The serum UA levels in patients with stable angina were significantly lower than those in patients with unstable angina and MI \text{ (one-way ANOVA, } P_{\text{SAP vs. MI}} < 0.05, \text{ and } P_{\text{SAP vs. UAP}} < 0.05, \text{ Table 3). When all EOCAD patients with MI were divided into 3 groups according to the number of diseased vessels, serum UA levels were } 5.783 \pm 1.411 \text{ mg/dl \((n = 326), 5.799 \pm 1.503 \text{ mg/dl \((n = 199), \text{ and } 6.322 \pm 1.554 \text{ mg/dl \((n = 295), \text{ respectively.}}

}\text{Table 1: Demographic and clinical characteristics of EOCAD patients and controls.}

| Variable | EOCAD \((n = 1093)\) | Control \((n = 1117)\) | \(P\) value |
|----------|------------------|------------------|----------|
| Gender, male \(n (\%)\) | 986 \((90.21)\) | 1015 \((90.86)\) | 0.597 |
| Age, years* | 43.90 \(\pm 4.61\) | 43.83 \(\pm 4.52\) | 0.693 |
| BMI (kg/m\(^2\))* | 26.78 \(\pm 3.61\) | 24.75 \(\pm 3.38\) | <0.001 |
| Hypertension, \(n (\%)\) | 314 \((28.73)\) | 320 \((27.31)\) | 0.578 |
| Diabetes, \(n (\%)\) | 214 \((19.58)\) | 46 \((4.12)\) | <0.001 |
| Smoking, \(n (\%)\) | 533 \((48.76)\) | 446 \((41.72)\) | <0.001 |
| Drinking, \(n (\%)\) | 677 \((61.94)\) | 415 \((39.92)\) | <0.001 |
| FBG, mmol/l* | 6.06 \(\pm 2.57\) | 5.43 \(\pm 1.63\) | <0.001 |
| TC, mmol/l* | 2.15 \(\pm 1.84\) | 1.45 \(\pm 1.13\) | <0.001 |
| HDL-C, mmol/l* | 4.54 \(\pm 1.29\) | 4.52 \(\pm 1.96\) | 0.635 |
| Lp(a), mmol/l* | 1.08 \(\pm 0.27\) | 1.27 \(\pm 0.33\) | <0.001 |
| SCr, \(\mu\text{mol/l}\) | 73.33 \(\pm 15.86\) | 75.14 \(\pm 13.81\) | 0.139 |
| UA, \(\mu\text{mol/l}\) | 5.843 \(\pm 1.479\) | 5.433 \(\pm 1.529\) | <0.001 |
| Male, \(\mu\text{mol/l}\) | 5.965 \(\pm 1.442\) | 5.560 \(\pm 1.492\) | <0.001 |
| Female, \(\mu\text{mol/l}\) | 4.718 \(\pm 1.343\) | 4.178 \(\pm 1.311\) | 0.004 |
| Myocardial infarction, \(n (\%)\) | 633 \((57.91)\) | — | — |
| 1-vessel disease, \(n (\%)\) | 326 \((51.50)\) | — | — |
| 2-vessel disease, \(n (\%)\) | 199 \((31.44)\) | — | — |
| 3-vessel disease, \(n (\%)\) | 108 \((17.06)\) | — | — |

EOCAD: early-onset coronary artery disease; BMI: body mass index; FBG: fasting blood glucose; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Lp (a): lipoprotein (a); Scr: serum creatinine; UA: uric acid. ∗Continuous variables are expressed as mean ± SD. The \(P\) value of the continuous variables was calculated by the unpaired \(t\)-test. ∗Categorical variables are expressed as percentages. The \(P\) value of the categorical variables was calculated by the \(\chi^2\) test.
(n = 108) in MI patients with 1–3-vessel disease. We detected a significant difference in the three groups (one-way ANOVA, P < 0.01). Levels of serum UA in the group with 3-vessel disease were significantly higher than those in groups with 1-vessel disease and 2-vessel disease (one-way ANOVA, P_{1vs.3} < 0.01 and P_{2vs.3} < 0.01, Table 3).

Hyperuricemia was defined as serum UA ≥7 mg/dl in men or ≥6 mg/dl in women. The Gensini score was 56.33 ± 45.80 in male EOCAD patients with hyperuricemia (n = 222) and 48.25 ± 37.23 in male EOCAD patients without hyperuricemia (n = 764, unpaired t-test, P < 0.05, unpaired t-test, P < 0.001).

**Figure 1:** The influence factors of serum uric acid levels in EOCAD patients. (a) Male controls with drinking status (5.713 ± 1.505 mg/dl) had significantly higher serum uric acid levels than male controls without drinking status (5.463 ± 1.483 mg/dl, unpaired t-test, P = 0.009). (b) Correlation between serum uric acid and SCr in EOCAD patients (r = 0.323, P < 0.001). (c) Correlation between serum uric acid and weight in controls (r = 0.327, P < 0.001).

**Figure 2:** Serum uric acid levels in EOCAD and control groups. Serum uric acid levels in EOCAD patients (5.843 ± 1.479 mg/dl) were significantly increased when compared with that in healthy controls (5.433 ± 1.529 mg/dl, unpaired t-test, P < 0.001).

**Figure 3:** Comparing serum uric acid levels in EOCAD and control group by gender. Serum uric acid levels in the male and female group. Serum uric acid levels were significantly higher in the female EOCAD group (4.718 ± 1.311 mg/dl) than in the female control group (4.178 ± 1.311 mg/dl, unpaired t-test, P = 0.04). The same relationship was also detected in male EOCAD (5.965 ± 1.442 mg/dl) and male control group (5.560 ± 1.492 mg/dl, unpaired t-test, P < 0.001).
Table 2: Associations between serum uric acid and risk of EOCAD.

| Model:                                      | OR 95% CI   | \( P \) value |
|---------------------------------------------|-------------|---------------|
| Model 1: crude, no adjustment               | —           | <0.001        |
| Model 2: adjusting for age, gender, BMI, diabetes, hypertension, smoking status, and drinking status | 1.150 (1.075–1.229) | <0.001        |
| Model 3: adjusting for FBG, LDL-C, SCr, TG, TC, HDL-C, and Lp(a) | 1.139 (1.065–1.218) | <0.001        |
| Model 4: adjusting for all these factors    | 1.100 (1.022–1.185) | 0.011         |

BMI: body mass index; FBG: fasting blood glucose; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SCr: serum creatinine; Lp (a): lipoprotein (a).

Table 3: The serum UA levels and severity of EOCAD.

| Subtype of EOCAD | \( n \) | UA (mg/dl) | \( P \) value* |
|------------------|--------|------------|---------------|
| SAP              | 222    | 5.554 ± 1.419 | \( P_{\text{SAP vs. MI}} < 0.05 \) |
| UAP              | 344    | 5.886 ± 1.505 | \( P_{\text{UAP vs. MI}} > 0.05 \) |
| MI               | 633    | 5.880 ± 1.479 | \( P_{\text{SAP vs. UAP}} < 0.05 \) |

Number of diseased vessels in MI

| Number of diseased vessels in MI | \( n \) | UA (mg/dl) | \( P \) value* |
|----------------------------------|--------|------------|---------------|
| 1-vessel disease                 | 326    | 5.783 ± 1.411 | \( P_{1v,2} > 0.05 \) |
| 2-vessel disease                 | 199    | 5.799 ± 1.503 | \( P_{1v,3} < 0.01 \) |
| 3-vessel disease                 | 108    | 6.322 ± 1.554 | \( P_{2v,3} < 0.01 \) |

EOCAD: early-onset coronary artery disease; UA: uric acid; SAP: stable angina; UAP: unstable angina; MI: myocardial infarction. *The \( P \) value was calculated by one-way ANOVA.

Table 4: Association of serum uric acid categories and Gensini score in male and female EOCAD patients.

| Variable                  | Normouricemia (<7.0 mg/dl) | Hyperuricemia (≥7.0 mg/dl) | \( P \) value* | Female EOCAD patients | Normouricemia (<6.0 mg/dl) | Hyperuricemia (≥6.0 mg/dl) | \( P \) value* |
|---------------------------|-----------------------------|----------------------------|---------------|-----------------------|-----------------------------|----------------------------|---------------|
| Number, \( n \)          | 764                         | 222                        | —             | 82                    | 24                          | —                          | —             |
| Age, years                | 43.74 ± 4.55                | 43.40 ± 1.99               | 0.333         | 46.18 ± 3.59          | 45.18 ± 3.06                | 0.379                      |               |
| BMI                       | 26.59 ± 3.54                | 27.86 ± 3.65               | <0.001        | 25.94 ± 3.52          | 25.98 ± 4.07                | 0.967                      |               |
| FBG, mmol/l               | 6.07 ± 2.53                 | 5.72 ± 2.06                | 0.067         | 6.59 ± 3.29           | 8.04 ± 5.11                 | 0.197                      |               |
| TG, mmol/l                | 2.01 ± 1.53                 | 2.78 ± 2.49                | <0.000        | 1.83 ± 2.10           | 1.63 ± 0.50                 | 0.744                      |               |
| TC, mmol/l                | 4.52 ± 1.27                 | 4.65 ± 1.38                | 0.170         | 4.45 ± 1.17           | 4.40 ± 2.36                 | 0.953                      |               |
| HDL-C, mmol/l             | 1.07 ± 0.26                 | 1.03 ± 0.25                | 0.057         | 1.12 ± 0.29           | 1.04 ± 0.23                 | 0.042                      |               |
| LDL-C, mmol/l             | 2.64 ± 0.97                 | 2.59 ± 1.02                | 0.586         | 2.45 ± 0.86           | 2.69 ± 1.93                 | 0.686                      |               |
| Lp(a), mmol/l             | 289.96 ± 344.69             | 262.95 ± 281.29            | 0.286         | 331.47 ± 345.69       | 257.07 ± 193.18             | 0.486                      |               |
| SCr, μmol/l               | 85.71 ± 14.80               | 92.55 ± 15.89              | <0.001        | 69.65 ± 14.31         | 77.48 ± 13.46               | 0.017                      |               |
| Gensini score             | 48.25 ± 37.23               | 56.33 ± 45.80              | \( 0.017 \)   | 26.22 ± 22.50         | 71.77 ± 64.33               | \( 0.044 \)                |               |

EOCAD: early-onset coronary artery disease; BMI: body mass index; FBG: fasting blood glucose; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Lp (a): lipoprotein (a); SCr: serum creatinine; UA: uric acid. *Continuous variables are expressed as mean ± SD. The \( P \) value of the continuous variables was calculated by unpaired \( t \)-test.

Table 4). In female EOCAD patients, the Gensini score was 71.77 ± 64.33 in patient with hyperuricemia (\( n = 82 \)) and only 26.22 ± 22.50 in female EOCAD without hyperuricemia (\( n = 24 \), unpaired \( t \)-test, \( P < 0.05 \), Table 4).

4. Discussion

The present study demonstrated that (1) the serum UA levels were significantly elevated in EOCAD patients, and the serum UA was an independent risk factor for EOCAD. (2) Serum UA levels were associated with disease severity. (3) The serum UA levels were influenced with drinking status and were positively correlated with SCr and weight.

UA is a final product of purine metabolism, formed from the breakdown of adenosine and guanine. The transformation of hypoxanthine into xanthine and of the latter into allantoin, which is freely excreted into the urine [15]. UA is degraded by the urate oxidase, to allantoin, which is finally reabsorbed in the proximal tubule, secreted, and reabsorbed [17]. Normal
serum levels of UA are generally 6.5 to 7 mg/dl for men and 6 to 6.5 mg/dl for women. Elevated serum UA is the result of overproduction or under excretion.

The positive association between serum UA and cardiovascular disease was recognized for 60 years. A number of epidemiologic studies have reported a relation between serum UA levels and a wide variety of cardiovascular conditions, including hypertension [18], metabolic syndrome [19], CAD [20], cerebrovascular disease [21], vascular dementia [21], and preeclampsia [22]. In the process of UA production, oxidants generated via xanthine oxidase may impair nitric oxide synthesis and availability [23]. UA could induce the proliferation and proinflammation of vascular smooth muscle cells [24]. Studies show that UA could induce CRP expression in endothelial cells, and this finding may provide further direct evidence for both proinflammatory and proatherogenic effects of UA [25]. Hyperuricemia is a frequent finding in insulin-resistant states and plays an important role in dysregulation of glucose uptake [26]. All these damage effects of UA were associated with endothelial dysfunction and finally lead to cardiovascular disease.

To compare with late-onset CAD, EOCAD may have different pathogenic mechanisms. Numerous studies have discovered so many biomarkers on EOCAD, including genes, proteins, and other bio-macromolecules [27, 28]. Our previous studies found that the MTHFR gene C677T polymorphism was associated with the risk of early-onset MI in Caucasians (OR = 1.275, 95% CI: 1.077–1.509) [14], and serum ADMA levels were associated with the presence and severity of EOCAD [29]. To our knowledge, only two studies explored the association between serum UA and risk of EOCAD in recent years. Otherwise, the debate as to whether UA plays an independent causal role in the development of CAD has intensified recently with many reviews and editorials providing differing views and recent studies providing conflicting results [30]. Zand et al.’s study only involved 245 EOCAD patients and 228 normal coronary subjects. They found that UA was significantly related to the presence of EOCAD, but it is not an independent risk factor for EOCAD [31]. Dai and coworkers demonstrated that higher serum UA level might play an important role in the severity of EOCAD in 786 patients. Because of the lack of the control group, the study could not discuss whether serum UA was an independent risk factor for EOCAD [32]. In our present study, we evaluate the association between serum UA levels and risk of EOCAD in 2210 participants (1093 patients and 1117 controls). The positive results were detected. Binary logistic regression clearly demonstrated that the serum UA levels were influenced by drinking status and were positively correlated with SCr and weight.

The current study should be considered as a preliminary report which has some limitations. First, a control group comprised age- and sex-matched individuals without any signs or symptoms of CAD and having a normal result of routine blood tests. We cannot exclude that since coronary angiography has not been performed in all the controls. Second, the findings are based on cross-sectional data and only measured serum UA at first hospital admission. A temporal association between serum UA and development of EOCAD cannot be inferred with certainty.

5. Conclusions
In conclusion, we observed that increased serum UA levels were associated with EOCAD and first indicated that serum UA is an independent risk factor for the disease. We also demonstrated that the serum UA levels were associated with disease severity, affected with drinking status, and were positively correlated with SCr and weight. The findings may be useful in understanding the mechanism and predicting progression of patients with EOCAD and may contribute to the further prevention of the disease.

Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest
The authors declare that they have no competing interests.

Acknowledgments
The work was fully supported by grants from the National Natural Science Foundation of China (no. 81672073) and the China Postdoctoral Science Foundation (no. 2016M590620).

Authors’ Contributions
TT and HL participated in the acquisition of data and performed the statistical analysis. SC, QW, QT, and BZ performed the statistical analysis. JZ revised the manuscript. GWH and LML revised the manuscript for important intellectual content. All authors read and approved the final manuscript. CX carried out substantial contribution to the study conception and design, analysis and interpretation of the data, and drafting of the manuscript.

References
[1] D. I. Feig, D. H. Kang, and R. J. Johnson, “Uric acid and cardiovascular risk,” The New England Journal of Medicine, vol. 359, no. 17, pp. 1811–1821, 2008.
[2] J. Maiuolo, F. Oppedisano, S. Gratteri, C. Muscoli, and V. Mollace, “Regulation of uric acid metabolism and
excretion,” *International Journal of Cardiology*, vol. 213, pp. 8–14, 2016.

[3] M. Jin, F. Yang, I. Yang et al., “Uric acid, hyperuricemia and vascular diseases,” *Frontiers in Bioscience*, vol. 17, no. 1, pp. 656–669, 2012.

[4] C. Xuan, F. J. Chang, X. C. Liu et al., “Endothelial nitric oxide synthase enhancer for protection of endothelial function from asymmetric dimethylarginine-induced injury in human internal thoracic artery,” *The Journal of Thoracic and Cardiovascular Surgery*, vol. 144, no. 3, pp. 697–703, 2012.

[5] C. Xuan, L. M. Lun, J. X. Zhao et al., “L-citrulline for protection of endothelial function from ADMA–induced injury in porcine coronary artery,” *Scientific Reports*, vol. 5, no. 1, article 10987, 2015.

[6] I. Papežíková, M. Pekarová, H. Kolárová et al., “Uric acid modulates vascular endothelial function through the regulation of nitric oxide production,” *Free Radical Research*, vol. 47, no. 2, pp. 82–88, 2013.

[7] T. Szasz and S. W. Watts, “Uric acid does not affect the acetylcholine-induced relaxation of aorta from normotensive and deoxycorticosterone acetate-salt hypertensive rats,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 333, no. 3, pp. 758–763, 2010.

[8] G. Ng, E. M. T. Chau, and Y. Shi, “Recent developments in immune activation by uric acid crystals,” *Archivum Immunologicum et Therapiae Experimentalis*, vol. 58, no. 4, pp. 273–277, 2010.

[9] D. B. Corry, P. Eslamí, K. Yamamoto, M. D. Nyby, H. Makino, and M. L. Tuck, “Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system,” *Journal of Hypertension*, vol. 26, no. 2, pp. 269–275, 2008.

[10] G. Fenech, G. Rajzbaum, M. Mazighi, and J. Blacher, “Serum uric acid and cardiovascular risk: state of the art and perspectives,” *Joint Bone Spine*, vol. 81, no. 5, pp. 392–397, 2014.

[11] E. R. Hauser, D. C. Crossman, C. B. Granger et al., “A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD study,” *The American Journal of Human Genetics*, vol. 75, no. 3, pp. 436–447, 2004.

[12] N. Pancharuniti, C. A. Lewis, H. E. Sauberlich et al., “Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease,” *The American Journal of Clinical Nutrition*, vol. 59, no. 4, pp. 940–948, 1994.

[13] I. Janszky, S. Ahnve, I. Lundberg, and T. Hemmingsson, “Early-onset depression, anxiety, and risk of subsequent coronary heart disease: 37-year follow-up of 49,321 young Swedish men,” *Journal of the American College of Cardiology*, vol. 56, no. 1, pp. 31–37, 2010.

[14] C. Xuan, X. Y. Bai, G. Gao, Q. Yang, and G. W. He, “Association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T and risk of myocardial infarction: a meta-analysis for 8,140 cases and 10,522 controls,” *Archives of Medical Research*, vol. 42, no. 8, pp. 677–685, 2011.

[15] S.-i. Yamagishi, Y. Ishibashi, A. Ojima, T. Sugihara, and T. Matsui, “Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity,” *International Journal of Cardiology*, vol. 176, no. 2, pp. 550–552, 2014.

[16] I. Žíňanová, P. Korytář, O. I. Arooja et al., “Uric acid and allantoin levels in Down syndrome: antioxidative and oxidative stress mechanisms?” *Clinica Chimica Acta*, vol. 341, no. 1-2, pp. 139–146, 2004.

[17] M. H. Alderman, “Serum uric acid as a cardiovascular risk factor for heart disease,” *Current Hypertension Reports*, vol. 3, no. 3, pp. 184–189, 2001.

[18] M. Kuvabara, I. Hisatome, K. Niwa et al., “Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study,” *Hypertension*, vol. 71, no. 1. pp. 78–86, 2018.

[19] T. Y. Yu, J. H. Jee, J. C. Bae et al., “Serum uric acid: a strong and independent predictor of metabolic syndrome after adjusting for body composition,” *Metabolism*, vol. 65, no. 4, pp. 432–440, 2016.

[20] S. Biscaglia, C. Ceconi, M. Malagù, R. Pavasini, and R. Ferrari, “Uric acid and coronary artery disease: an elusive link deserving further attention,” *International Journal of Cardiology*, vol. 213, pp. 28–32, 2016.

[21] X. Zhang, Z. C. Huang, T. S. Lu, S. J. You, Y. J. Cao, and C. F. Liu, “Prognostic significance of uric acid levels in ischemic stroke patients,” *Neurotoxicity Research*, vol. 29, no. 1, pp. 10–20, 2016.

[22] Y. Wu, X. Xiong, W. D. Fraser, and Z. C. Luo, “Association of uric acid with progression to preeclampsia and development of adverse conditions in gestational hypertensive pregnancies,” *American Journal of Hypertension*, vol. 25, no. 6, pp. 711–717, 2012.

[23] C. Gersch, S. P. Palii, K. M. Kim, A. Angerhofer, R. J. Johnson, and G. N. Henderson, “Inactivation of nitric oxide by uric acid,” *Nucleosides, Nucleotides and Nucleic Acids*, vol. 27, no. 8, pp. 967–978, 2008.

[24] J. Kanelis, S. Watanabe, J. H. Li et al., “Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2,” *Hypertension*, vol. 41, no. 6, pp. 1287–1293, 2003.

[25] D. H. Kang, S. K. Park, I. K. Lee, and R. J. Johnson, “Uric acid–induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells,” *Journal of the American Society of Nephrology*, vol. 16, no. 12, pp. 3553–3562, 2005.

[26] A. Quinones Galvan, A. Natali, S. Baldi et al., “Effect of insulin on uric acid excretion in humans,” *American Journal of Physiology-Endocrinology and Metabolism*, vol. 268, no. 1, pp. E1–E5, 1995.

[27] Y. Wang, A. Zheng, Y. Yan et al., “Association between HMW adiponectin, HMW-total adiponectin ratio and early-onset coronary artery disease in Chinese population,” *Atherosclerosis*, vol. 235, no. 2, pp. 392–397, 2014.

[28] C. Ward-Caviness, C. Haynes, C. Blach et al., “Gene–smoking interactions in multiple Rho-GTPase pathway genes in an early-onset coronary artery disease cohort,” *Human Genetics*, vol. 132, no. 12, pp. 1371–1382, 2013.

[29] C. Xuan, Z. F. Liu, Q. Wang et al., “Increased serum concentrations of asymmetric dimethylarginine (ADMA) in patients with early-onset coronary artery disease,” *Clinical Chimica Acta*, vol. 464, pp. 195–199, 2017.

[30] S. G. Wannamethee, “Serum uric acid is not an independent risk factor for coronary heart disease,” *Current Hypertension Reports*, vol. 3, no. 3, pp. 190–196, 2001.
[31] S. Zand, A. Shafiee, M. Boroumand, A. Jalali, and Y. Nozari, “Serum uric acid is not an independent risk factor for premature coronary artery disease,” Cardiorenal Medicine, vol. 3, no. 4, pp. 246–253, 2013.

[32] X. M. Dai, L. Wei, L. L. Ma et al., “Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease,” Clinical Rheumatology, vol. 34, no. 9, pp. 1605–1611, 2015.